L3VLUP
ProSign in

WAT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

WATLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • WAT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterWATLLY
Q3 202022 holders, $1.9bn33 holders, $14.1bn
Q4 202017 holders, $2.1bn29 holders, $17.3bn
Q1 202115 holders, $2.2bn24 holders, $23.0bn
Q2 202116 holders, $2.5bn24 holders, $27.8bn
Q3 202118 holders, $2.8bn31 holders, $29.9bn
Q4 202114 holders, $3.1bn31 holders, $34.7bn
Q1 202217 holders, $2.4bn24 holders, $35.3bn
Q2 202218 holders, $2.7bn33 holders, $42.7bn
Q3 202219 holders, $2.2bn31 holders, $43.4bn
Q4 202221 holders, $2.5bn31 holders, $46.6bn
Q1 202323 holders, $2.5bn33 holders, $44.3bn
Q2 202315 holders, $2.3bn37 holders, $59.6bn
Q3 202314 holders, $2.4bn44 holders, $67.6bn
Q4 20238 holders, $2.6bn45 holders, $73.6bn
Q1 20248 holders, $2.8bn41 holders, $95.3bn
Q2 202410 holders, $2.1bn43 holders, $110bn
Q3 20247 holders, $2.5bn45 holders, $107bn
Q4 202410 holders, $2.8bn46 holders, $93.9bn
Q1 202511 holders, $3.1bn42 holders, $98.4bn
Q2 202512 holders, $3.3bn43 holders, $93.2bn
Q3 202512 holders, $2.6bn39 holders, $86.7bn
Q4 202515 holders, $3.9bn41 holders, $123bn
Q1 202618 holders, $6.6bn39 holders, $106bn
Q2 202620 holders, $9.8bn44 holders, $132bn
WAT

Waters Corp

Holders
10
Reported value
$2.8bn
Buyers
7
Sellers
3

Breadth +4 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only WAT (0)

None.

Only LLY (36)

Acadian Asset Management LLC, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Lone Pine Capital LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Rokos Capital Management LLP, and 11 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →